Reports Q4 revenue $1.39B, consensus $1.36B. Q4 TAVR sales grew 6%; constant currency sales grew 5%; Q4 TMTT sales grew 88% to $105 million ...

With new transcatheter options for the repair or replacement of tricuspid valves, the role and timing of repair — whether surgical or minimally invasive — is entering a time of transition.

Pressing down on your fingernails could reveal a subtle yet serious indicator of heart trouble, according to a doctor. Pulsating hues of pink and white beneath the nail bed may signal a critical ...

An expert has issued a warning to people if they notice a specific sign when pressing down on the fingernails.

We came across a bullish thesis on Edwards Lifesciences Corporation (EW) on Substack by Natan. In this article, we will ...

New 20-year data show a survival rate of 90% with few repeat surgeries after this complex operation that can only be performed by highly trained specialists.

“Freedom from aortic regurgitation was 95.1%, 92.2%, 87.7%, and 84.5% at 5,10,15 and 20 years respectively,” the researchers reported. Freedom from pulmonary regurgitation was lower—97% at 5 years, 83 ...

"As an aside, the Ross procedure, which is my preference in this age group, is the only aortic valve replacement procedure that results in a late survival curve equivalent to an a ...

The Trilogy valve. [Image from the JenaValve website] GlobalData analysts anticipate FDA approval for the JenaValve Trilogy TAVR device designed to treat aortic regurgitation (AR) this year.

device designed for aortic regurgitation (AR), by late 2025. This approval will mark a significant step forward, expanding TAVR’s treatment indications to include AR — a condition previously ...